Marcel Miron-Celis: The Largest Cohort Ever Studied on Perioperative Management of Thrombotic APS
Marcel Miron-Celis, Data Scientist at MDClone, shared Joseph R. Shaw‘s post on LinkedIn, adding:
“If you are a physician interested in the perioperative management of patients with thrombotic antiphospholipid syndrome, then you should read this awesome research paper that I worked on with my previous colleagues at The Ottawa Hospital.
Largest cohort ever studied on this topic, with very interesting findings!”
Joseph R. Shaw, Director of Research and Program at Ottawa Department of Medicine, EHJ-CVP Associate Editor of European Heart Journal, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Blood Advances, adding:
”I’m pleased to share that our paper, ‘Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome,’ has been published in Blood Advances.
This project grew out of a practical and difficult question we face often in thrombosis care: how should we manage anticoagulation interruption in patients with thrombotic APS who need surgery or an invasive procedure?
Data to guide these decisions is limited.
In this study, we evaluated 172 adults with thrombotic APS who underwent 282 planned perioperative anticoagulation interruptions between 2016 and 2025.
To our knowledge, this is the largest single-center cohort focused on perioperative anticoagulation management in thrombotic APS.
A few key findings stood out to me:
- Bridging was commonly used, and clinicians appeared to individualize management based on APS phenotype and prior thrombotic history.
- Patients with triple-positive APS and those with prior arterial thromboembolism were more likely to receive therapeutic-dose LMWH bridging.
Overall, 30-day outcomes were reassuring: the risks of arterial thromboembolism and major bleeding were both 0.7%, while clinically relevant nonmajor bleeding occurred in 3.2% of interruptions.
The take-home message: individualized, risk-adapted perioperative anticoagulation management that considers APS-related thrombotic risk, procedural bleeding risk, and clinical context appears feasible and safe in thrombotic APS.
At the same time, high-risk phenotypes – especially triple-positive APS and prior arterial events – still require careful planning and vigilance.
A special congratulations to Miguel Paquette.
This paper reflects his hard work, persistence, and attention to detail, and I’m very glad to see these important results published in Blood Advances.”
Title: Perioperative management of antithrombotic therapy in patients with thrombotic antiphospholipid syndrome
Authors: Miguel Paquette, Sébastien Miranda, Yan Xu, Leslie Skeith, Marcel Miron-Celis, Ronald A. Booth, Hakan Buyukdere, Deborah M. Siegal, Grégoire Le Gal, Marc Carrier, James D. Douketis, Jerrold H. Levy, Jean M. Connors, Aurélien Delluc, Joseph R. Shaw
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 4, 2026, 13:58Dietmar Dammerer: How Should We Manage Traumatic Brain Injury When on Anticoagulants?
-
Jun 4, 2026, 13:54Yaariv Khaykin: AI ECG Analysis Uncovers Hidden AF Associated With Future Stroke Risk
-
Jun 4, 2026, 13:50Gene Nudelman: Can a Hemostatic Gauze Perform When Blood Clotting is Impaired?
-
Jun 4, 2026, 13:45Edward Lee Carter: The First-Ever AHA/ACC Acute PE Guideline Is Here
-
Jun 4, 2026, 13:38Denis Oduor: The Role of Expectant Fathers in Saving Mothers and Newborns
-
Jun 4, 2026, 13:36Mohammad Reza Moghaddasnejad: Platelet Activation as a Key Driver of Breast Cancer Progression
-
Jun 4, 2026, 13:31Fredrick Chalinga: Microcytic Anemia Does Not Always Mean Iron Deficiency
-
Jun 4, 2026, 13:23How Access to Care Changed One Life – WFH
-
Jun 4, 2026, 13:16Muhammad Usman Arshad: Meta-Analysis Supports Expanding Role of DOACs in Cancer-Associated Thromboembolism